VERTEX PHARMACEUTICALS INC / MA
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $12.0B | $11.0B | $9.9B | $8.9B | $7.6B |
| Operating income | $4.2B | -$232.9M | $3.8B | $4.3B | $2.8B |
| Cost of revenue | $1.7B | $1.5B | $1.3B | $1.1B | $904.2M |
| Cash from operations | $3.6B | -$492.6M | $3.5B | $4.1B | $2.6B |
| Capital expenditure | $437.6M | $297.7M | $200.4M | $204.7M | $235.0M |
| Free cash flow | $3.2B | -$790.3M | $3.3B | $3.9B | $2.4B |
| Share repurchases | $2.0B | $1.2B | $427.6M | $0 | $1.4B |
| Impairments | $379.0M | $0 | $0 | — | — |
| Total assets | $25.6B | $22.5B | $22.7B | $18.2B | $13.4B |
| Total liabilities | $7.0B | $6.1B | $5.1B | $4.2B | $3.3B |
Shares outstanding 253.8M · Free float 99.8%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.